The information in this site is intended for healthcare professionals in New Zealand and is not intended for the general public.
The information contained on this website is intended for New Zealand healthcare professionals only and is intended to be used for educational purposes only. It does not cover all available information. EpiPen (adrenaline 300mcg/0.3ml) and EpiPen Jr (adrenaline 150mcg/0.3ml) Auto-Injector. Medicine Classification: Restricted medicine. Indications: For the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, or bites, foods, medications or other allergens. Contraindications: Arrhythmias, cerebral arteriosclerosis; maternal hypertension in excess of 130/80; shock (other than anaphylactic shock), organic brain damage, or during general anaesthesia with halogenated hydrocarbons or cyclopropane, and in patients where vasopressor drugs are contraindicated. Precautions: Patients with allergies to sulphites, cardiac dilation, ventricular fibrillation, myocardial infarction and other heart conditions, elderly, diabetes and other diseases. Interactions: Concomitant use with other sympathomimetic agents not advised. Caution in combination with CNS agents; TCAs; MAOIs; levothyroxine and thyroid hormones; some antihistamines; alpha-adrenergic blocking agents; beta-adrenergic blocking agents; digoxin; quinidine; general anaesthetics; hypoglycaemic agents. See datasheet for more information and incompatibilities. Adverse Effects: Potentially fatal ventricular arrhythmias, including ventricular fibrillation may occur and severe hypertension may lead to cerebral haemorrhage and pulmonary oedema. Other symptomatic adverse events can occur. Dosage & Administration: EpiPen delivers a single 300μg intramuscular dose of adrenaline and should only be used in patients weighing more than 30 kg. EpiPen Jr delivers a single 150μg intramuscular dose of adrenaline and should only be used in children weighing 15kg to 30kg. EpiPen and EpiPen Jr are non-funded medicines. Patients are required to pay the full cost. Before recommending this medicine please refer to full datasheet available from EpiPen® is a registered trademark of Mylan Inc. Mylan New Zealand Limited, Auckland. TAPS: DA0314DS-17.